Effectiveness and Tolerability of Adding Ezetimibe to Niacin-Based Regimens for Treatment of Primary Hyperlipidemia

Kashyap, 2002, Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia, Am J Cardiol., 89, 672, 10.1016/S0002-9149(01)02338-4 Duvall, 2002, Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy, J Cardiovasc Risk., 9, 339, 10.1177/174182670200900607 Wolfe, 2001, Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia, Am J Cardiol., 87, 476, 10.1016/S0002-9149(00)01410-7 Davidson, 2004, Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia, Int J Clin Pract., 58, 746, 10.1111/j.1368-5031.2004.00289.x Xydakis, 2004, Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia, Am J Cardiol., 94, 795, 10.1016/j.amjcard.2004.06.008 Guyton, 2000, Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol, Arch Intern Med., 160, 1177, 10.1001/archinte.160.8.1177 Carlson, 1988, Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid, Acta Med Scand., 223, 405, 10.1111/j.0954-6820.1988.tb15891.x Cashin-Hemphill, 1990, Beneficial effects of colestipol-niacin on coronary atherosclerosis: a 4-year follow-up, JAMA., 264, 3013, 10.1001/jama.1990.03450230049028 Brown, 2001, Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease, N Engl J Med., 345, 1583, 10.1056/NEJMoa011090 Taylor, 2004, Circulation., 110, 3512, 10.1161/01.CIR.0000148955.19792.8D Ballantyne, 2004, Role of selective cholesterol absorption inhibition in the management of dyslipidemia, Curr Atheroscler Rep., 6, 52, 10.1007/s11883-004-0116-4 Gagne, 2002, Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia, Am J Cardiol., 90, 1084, 10.1016/S0002-9149(02)02774-1 Cheung, 2001, Antioxidant supplements block the response of HDL to simvastatin-niacin therapy in patients with coronary artery disease and low HDL, Arterioscler Thromb Vasc Biol., 21, 1320, 10.1161/hq0801.095151 Friedewald, 1972, Estimation of the concentration of low-density lipoprotein in plasma, without use of the preparative ultracentrifuge, Clin Chem., 18, 499, 10.1093/clinchem/18.6.499 Altschul, 1955, Influence of nicotinic acid on serum cholesterol in man [letter], Arch Biochem., 54, 558, 10.1016/0003-9861(55)90070-9 Guyton, 2004, Extended-release niacin for modifying the lipoprotein profile, Expert Opin Pharmacother., 5, 1385, 10.1517/14656566.5.6.1385 1975, JAMA., 231, 360, 10.1001/jama.1975.03240160024021 Davis, 2004, Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis, J Biol Chem., 279, 33586, 10.1074/jbc.M405817200 2006, Ezetimibe product information, 2090 Konpp, 2003, Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies, Int J Clin Pract., 57, 363, 10.1111/j.1742-1241.2003.tb10508.x Guyton, 1998, Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia, Am J Cardiol., 82, 737, 10.1016/S0002-9149(98)00448-2 Grundy, 2004, Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [erratum in Circulation. 2004;110:763], Circulation, 110, 227, 10.1161/01.CIR.0000133317.49796.0E